- Home
- SLNH vs CLDI Comparison
SLNH vs CLDI Comparison
Compare SLNH & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLNH | CLDI |
|---|---|---|
| Founded | 1961 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.8M | 9.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SLNH | CLDI |
|---|---|---|
| Price | $1.63 | $1.47 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.7M | 108.1K |
| Earning Date | 11-17-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $28,782,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $42.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.36 | $1.10 |
| 52 Week High | $5.14 | $25.32 |
Technical Indicators
Market Signals| Indicator | SLNH | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 41.53 | 48.58 |
| Support Level | $1.56 | $1.38 |
| Resistance Level | $1.91 | $1.55 |
| Average True Range (ATR) | 0.23 | 0.10 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 33.61 | 69.52 |
Price Performance
Historical ComparisonAbout SLNH Soluna Holdings Inc.
Soluna Holdings Inc is a U.S.-based company that conducts operations through its subsidiary. The group is engaged in the mining of cryptocurrency through data centers that can be powered by renewable energy sources. The data centers buy every excess megawatt to use for batch-oriented, computing-intensive processes such as cryptocurrency mining or machine learning which is a low-risk and low-friction solution to use as a smartphone.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.